UBS Group AG - CHINA BIOLOGIC PRODS HLDGS I ownership

Quarter-by-quarter ownership
UBS Group AG ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q1 2021$12,000
-96.9%
102
-96.9%
0.00%
Q4 2020$385,000
+474.6%
3,256
+439.1%
0.00%
Q3 2020$67,000
+17.5%
604
+7.5%
0.00%
Q2 2020$57,000
-41.8%
562
-38.0%
0.00%
Q1 2020$98,000
-90.2%
907
-89.5%
0.00%
Q4 2019$1,003,000
+83.0%
8,617
+79.9%
0.00%
Q3 2019$548,000
+483.0%
4,789
+382.3%
0.00%
Q2 2019$94,000
+1075.0%
993
+1041.4%
0.00%
Q1 2019$8,000
-89.7%
87
-91.4%
0.00%
Q4 2018$78,000
+1014.3%
1,016
+1067.8%
0.00%
Q3 2018$7,000
-99.6%
87
-99.5%
0.00%
-100.0%
Q2 2018$1,596,000
-52.7%
16,070
-61.5%
0.00%0.0%
Q1 2018$3,377,000
+89.3%
41,699
+84.1%
0.00%0.0%
Q4 2017$1,784,000
+2158.2%
22,645
+2536.2%
0.00%
Q3 2017$79,0008590.00%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q2 2021
NameSharesValueWeighting ↓
VERNIER CAPITAL PARTNERS, LP 137,557$11,142,0006.62%
COMGEST GLOBAL INVESTORS S.A.S. 637,752$51,658,0001.13%
Black Creek Investment Management Inc. 411,525$33,334,0001.09%
Hillhouse Capital Management 618,391$50,090,0000.88%
RUDMAN ERROL M 21,301$1,725,0000.83%
JUPITER ASSET MANAGEMENT LTD 263,705$21,360,0000.65%
York Capital Management Global Advisors, LLC 341,616$27,671,0000.62%
VONTOBEL ASSET MANAGEMENT INC 873,968$71,525,0000.51%
Temasek Holdings (Private) Ltd 990,000$80,190,0000.44%
WASATCH ADVISORS LP 292,216$23,669,0000.31%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders